Drug intelligence / Profile preview

NK1R-receptor antagonist

Development stage: Preclinical
Lead developer: Hamlet Biopharma
Modality: Small Molecules

Overview

NK1R-receptor antagonist is a preclinical drug candidate being developed by Hamlet BioPharma for the treatment of pain and conditions involving nerve activation. The drug functions as an antagonist of the Neurokinin-1 receptor (NK1R), which is the high-affinity receptor for the neuropeptide Substance P. Substance P and NK1R signaling are critical components of the pain transmission system and are involved in neurogenic inflammation. By inhibiting NK1R, this candidate aims to block the transmission of pain signals and reduce nerve-mediated inflammatory responses.

Other names: Neurokinin-1 receptor antagonistNeurokinin1 receptor antagonistNeurokinin 1 receptor antagonist

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on NK1R-receptor antagonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK1R-receptor antagonist.

Explore the full profile